Abstract
BackgroundSecondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma. Prognosis of SCNSL is poor and the most appropriate treatment is still undetermined.MethodsWe conducted a retrospective study to assess the feasibility of an R-MIADD (rituximab, high-dose methotrexate, ifosfamide, cytarabine, liposomal formulation of doxorubicin, and dexamethasone) regimen for SCNSL patients.ResultsNineteen patients with newly diagnosed CNS lesions were selected, with a median age of 58 (range 20 to 72) years. Out of 19 patients, 11 (57.9%) achieved complete remission (CR) and 2 (10.5%) achieved partial remission (PR); the overall response rate was 68.4%. The median progression-free survival after CNS involvement was 28.0 months (95% confidence interval 11.0–44.9), and the median overall survival after CNS involvement was 34.5 months. Treatment-related death occurred in one patient (5.3%).ConclusionsThese single-centered data underscore the feasibility of an R-MIADD regimen as the induction therapy of SCNSL, further investigation is warranted.
Highlights
Secondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma
autologous stem cell transplantation (ASCT) has been offered to only a small number of younger patients but elicited a favorable response .several studies have explored the effectiveness of non-transplant regimens for SCNSL and indicate that this could be an effective treatment for patients with SCNSL [10,11,12]
We reported the combination of an R-MAIDD regimen to treat SCNSL patients resulting in an overall response rate (ORR) of 68.4% and a post-CNS involvement progression-free survival (PFS) of 28.0 months
Summary
Secondary central nervous system lymphoma (SCNSL) is defined as lymphoma involvement within the central nervous system (CNS) that originated elsewhere, or a CNS relapse of systemic lymphoma. Secondary central nervous system lymphoma (SCNSL) refers to secondary involvement of the brain, eye, spine, meningeal by systemic lymphoma [1, 2] It is a devastating complication of systemic lymphoma, occurring in 5– 10% of diffuse large B cell lymphoma (DLBCL) patients with very few long-term survivors under conventional treatment [3]. ASCT has been offered to only a small number of younger patients but elicited a favorable response .several studies have explored the effectiveness of non-transplant regimens for SCNSL and indicate that this could be an effective treatment for patients with SCNSL [10,11,12] With this information in mind, we proceeded to treat SCNSL patients with the combination of rituximab, HD-MTX, ifosfamide, cytarabine, liposomal formulation of doxorubicin, or an R-MIADD regimen and carried out a retrospective study to explore the effectiveness and tolerance of this novel chemotherapeutic combination
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
